Connor, Clark & Lunn Investment Management (CC&L)
SWTX

Connor, Clark & Lunn Investment Management (CC&L)’s SpringWorks Therapeutics SWTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53,827
Closed -$1.54M – 1421
2022
Q3 		$1.54M Buy
53,827
+21,057
+64% +$604K 0.01% 560
2022
Q2 		$807K Buy
+32,770
New +$1.2M ﹤0.01% 670

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SWTX Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of SpringWorks Therapeutics (SWTX) in Q4 2022, closing a stake of 53,827 shares — an estimated $1.54M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SWTX in Q2 2022 and held it in 2 quarters. The position peaked at $1.54M in Q3 2022. 137 funds tracked by Wall St. Rank hold SWTX as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining SpringWorks Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 53,827 SpringWorks Therapeutics shares in Q4 2022, an estimated $1.54M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s SpringWorks Therapeutics position peaked at $1.54M in Q3 2022.
  • 137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.